Philip N Collier

USPTO Granted Patents = 13 (Patent Applications = 6)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 161(Granted Patents)

Location History:

Arlington, MA (US) (2013 - 2015)
Cambridge, MA (US) (2013 - 2019)
Hingham, MA (US) (2018 - 2020)

Company Filing History:

13 out of 1,149

Vertex Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195453 - Antiproliferation compounds and uses thereof (2025-01-14),

2. 10766869 - Triazoles for the treatment of demyelinating dieases (2020-09-08),

3. 10183933 - Isoindolinone inhibitors of phosphatidylinositol 3-kinase (2019-01-22),

4. 10118904 - Triazoles for the treatment of Demyelinating Diseases (2018-11-06),

5. 9676759 - Isoindolinone inhibitors of phosphatidylinositol 3-kinase (2017-06-13),

6. 9193722 - Tri-cyclic pyrazolopyridine kinase inhibitors (2015-11-24),

7. 8735593 - Aminopyridines useful as inhibitors of protein kinases (2014-05-27),

8. 8598361 - Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof (2013-12-03),

9. 8569337 - Tri-cyclic pyrazolopyridine kinase inhibitors (2013-10-29),

10. 8541445 - Pyrazolopyridines (2013-09-24),

11. 8466288 - Isoindolinone inhibitors of phosphatidylinositol 3-kinase (2013-06-18),

12. 8410133 - Aminopyridines useful as inhibitors of protein kinases (2013-04-02),

13. 8372850 - Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases (2013-02-12),

Title: The Innovative Contributions of Philip N. Collier

Introduction

Philip N. Collier is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceuticals. With a total of 13 patents to his name, Collier has made remarkable advancements in the treatment of various medical conditions, particularly those related to cellular proliferation and demyelinating diseases.

Latest Patents

Among his latest patents, Collier has developed antiproliferation compounds aimed at treating cellular proliferative disorders, such as cancer. This invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, along with pharmaceutical compositions and methods for their use. Additionally, he has created triazole compounds for the treatment of demyelinating diseases. These compounds, also represented by formulas I and I', serve as modulators for conditions like multiple sclerosis, offering new hope through their pharmaceutical compositions and treatment methods.

Career Highlights

Collier has had a distinguished career, working with leading companies in the pharmaceutical industry. Notably, he has been associated with Vertex Pharmaceuticals, Inc. and Merck Patent GmbH, where he has contributed to groundbreaking research and development efforts.

Collaborations

Throughout his career, Collier has collaborated with esteemed colleagues, including Juan-Miguel Jimenez and Robert J. Davies. These partnerships have fostered innovation and have been instrumental in advancing his research initiatives.

This text is generated by artificial intelligence and may not be accurate.